IDiyas

For the Inventor, By the Inventor

Lexington, MA, United States of America

Maria Alexandra Glucksmann

USPTO Granted Patents = 20 

Average Co-Inventor Count = 2.4

ph-index = 7

Forward Citations = 357(Granted Patents)


Location History:

  • Somerville, MA (US) (1999)
  • Lexington, MA (US) (2002 - 2009)

Company Filing History:

goldMedal19 out of 850 
 
Millennium Pharmaceuticals Limited
 patents
silverMedal1 out of 1,370 
 
The Brigham and Women's Hospital, Inc.
 patents
bronzeMedal1 out of 36 
 
Millenium Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1999-2009

Loading Chart...
20 patents (USPTO):
1. 7534579 - 14273 receptor, a novel G-protein coupled receptor (2009-05-19),
2. 7482147 - Ubiquitin protease (2009-01-27),
3. 7256010 - Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor (2007-08-14),
4. 7078205 - NUCLEIC ACID SEQUENCES ENCODING MELANOMA ASSOCIATED ANTIGEN MOLECULES, AMINOTRANSFERASE MOLECULES, ATPASE MOLECULES, ACYLTRANSFERASE MOLECULES, PYRIDOXAL-PHOSPHATE DEPENDENT ENZYME MOLECULES AND USES THEREFOR (2006-07-18),
5. 7057028 - 14273 Receptor, a novel G-protein coupled receptor (2006-06-06),
6. 7029895 - 27411, a novel human PGP synthase (2006-04-18),
7. 6979564 - 80090, human fucosyltransferase nucleic acid molecules and uses thereof (2005-12-27),
8. 6972187 - OAT5 molecules and uses therefor (2005-12-06),
9. 6953682 - Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor (2005-10-11),
10. 6900303 - 57658, a novel human uridine kinase and uses thereof (2005-05-31),
11. 6780627 - 22438, 23553, 25278, and 26212 novel human sulfatases (2004-08-24),
12. 6767727 - 22438, 23553, 25278, and 26212 novel human sulfatases (2004-07-27),
13. 6686185 - 25934, a novel fatty acid desaturase and uses therefor (2004-02-03),
14. 6586205 - 43239 a novel GPCR-like molecule and uses thereof (2003-07-01),
15. 6534302 - 22438, 23553, 25278, and 26212 novel human sulfatases (2003-03-18),

Title: Maria Alexandra Glucksmann: Innovator in Receptor-Mediated Therapeutics

Introduction

Maria Alexandra Glucksmann, based in Lexington, MA, is a prolific inventor with an impressive portfolio of 20 patents. Her work primarily focuses on innovative solutions in the field of G-protein coupled receptors, providing vital advancements in the diagnosis and treatment of various cardiovascular diseases.

Latest Patents

Among her notable inventions is the "14273 Receptor," a newly identified member of the G-protein coupled receptor superfamily. This invention encompasses polynucleotides that encode the receptor and introduces methods utilizing the receptor polypeptides and polynucleotides as targets for diagnosing and treating receptor-mediated disorders, particularly cardiovascular issues such as congestive heart failure. Moreover, she has developed drug-screening methods aimed at identifying agonists and antagonists for therapeutic purposes, along with procedures to produce the receptor polypeptides and polynucleotides.

Another significant contribution from Glucksmann is related to "Ubiquitin Protease." This invention provides isolated nucleic acid molecules and proteins, alongside a variety of nucleic acid sequences designated with numbers such as 27411, 23413, and many more. The invention facilitates the development of diagnostic and therapeutic methods using these compositions, significantly impacting medical research and treatment methodologies.

Career Highlights

Maria has garnered extensive experience working with esteemed organizations, including Millennium Pharmaceuticals Limited and Brigham and Women's Hospital, Inc. Her contributions to these institutions reflect her dedication to advancing the field of biomedical research.

Collaborations

Throughout her career, Glucksmann has collaborated with notable professionals in her domain, including Rachel E. Meyers and Mark Williamson. These partnerships have facilitated innovative advancements and broadened the scope of her research endeavors.

Conclusion

Maria Alexandra Glucksmann stands as a distinguished inventor whose work in receptor-mediated therapies holds great promise for the future of cardiovascular treatment. Her innovative patents and collaborative spirit underscore her commitment to enhancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…